**Question:** BRCA1 is responsible for which histological type of breast cancer?

A. Luminal A
B. Triple-negative
C. Her2-positive
D. Normal-like

**Core Concept:**
The BRCA1 gene is a tumor suppressor gene that plays a crucial role in maintaining genomic stability and preventing the development of cancer. Mutations in BRCA1 increase the risk of developing breast and ovarian cancers. These mutations primarily affect the ability of the cell to repair damaged DNA, leading to uncontrolled cell growth and the formation of tumors.

**Why the Correct Answer is Right:**
BRCA1 is primarily associated with triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer characterized by the lack of expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). In the context of BRCA1, TNBC is chosen as the correct answer because:

1. BRCA1 mutations increase the risk of TNBC development due to impaired DNA repair mechanisms.
2. TNBC is an aggressive subtype, which is consistent with the increased risk associated with BRCA1 mutations.

**Why Each Wrong Option is Incorrect:**

A. Luminal A: Luminal A breast cancer is a subtype characterized by the presence of ER and/or PR, but low HER2 expression. The wrong answer is incorrect because it does not reflect the BRCA1-associated risk and aggressive nature of the cancer.

B. Triple-negative: Although true for the general population, this option is incorrect because it does not specifically address the relationship between BRCA1 mutations and the mentioned histological type (TNBC).

C. Her2-positive: Her2-positive breast cancer is characterized by high HER2 expression. This option is incorrect as it contradicts the key feature of BRCA1-associated breast cancer, which is low HER2 expression.

D. Normal-like: Normal-like breast cancer refers to tumors with low molecular subtype classification. This option is incorrect as it does not address the relationship between BRCA1 mutations and the specific histological type (TNBC) mentioned in the question.

**Clinical Pearl:**
The understanding of BRCA1 mutations and their association with TNBC is crucial for healthcare professionals, as it helps guide patient management, prognosis, and treatment options for individuals with known BRCA1 mutations. For example, TNBC patients with a known BRCA1 mutation may benefit from platinum-based chemotherapy, PARP inhibitors, and targeted therapies, as well as increased surveillance to detect cancer at an earlier stage.